Table 1.
Baseline characteristics and previous therapies
| Japanese subgroup |
Overall populationa |
|||
|---|---|---|---|---|
| Everolimus (n = 23) | Placebo (n = 17) | Everolimus (n = 207) | Placebo (n = 203) | |
| Median age, years (range) | 45 (33–85) | 53 (38–77) | 58 (23–87) | 57 (20–82) |
| Male/female, % | 57:44 | 47:53 | 53:47 | 58:42 |
| WHO PS 0/1/2, % | 87/13/0 | 88/12/0 | 67/30/3 | 66/32/3 |
| No. disease sites 1/2/≥3, % | 30/35/35 | 29/29/41 | 25/41/34 | 31/32/38 |
| Histologic grade, % | ||||
| Well-differentiated | 100 | 94 | 82 | 84 |
| Moderately differentiated | 0 | 6 | 17 | 15 |
| Unknown | 0 | 0 | 1 | 1 |
| Previous therapies, % | ||||
| Chemotherapy | 61 | 53 | 50 | 50 |
| Radiotherapy | 13 | 12 | 23 | 20 |
| Targeted therapy | 0 | 0 | 5 | 7 |
| Immunotherapy | 0 | 0 | 3 | 4 |
| Hormone therapy | 0 | 0 | 1 | 1 |
| Other | 4 | 0 | 10 | 13 |
| Somatostatin analogues | 22 | 35 | 49 | 50 |
WHO PS, World Health Organization performance status.
aData previously presented by Yao JC et al. N Engl J Med. 2011;364: see also 514–23 (24).